Hello, I'm Egidijus Machtejevas.
I'm Lead Expert in Chromatography Product
and Portfolio Management at Merck in Darmstadt.
Today, we have a part 2 talk about the advantages of
using monolithic silica gel columns in the pharmaceutical industry.
Our focus topic today is biomolecule separation.
First of all, I would like to give you a short introduction about the bioseparation
itself and about our new wide pore monolithic column products.
Today, we have a new era in the pharmaceutical industry.
In the past, some years ago,
like 20 or more years ago,
90 percent of all therapeutics had been small molecules.
However, today's situation is different and we have a very clear focus on therapeutics,
which are large molecules.
These large molecules provide certain advantages,
like a delivery to target cells and tissues,
with less serious side effects.
But in terms of chromatography,
small molecules and large molecules differ quite significantly.
Of course, small molecules are small and large molecules,
they are much more complex and they are big in size.
Last but not least,
they have quite a number of different functionalization on the surface.
How would the chromatographic material be
different to accommodate these large molecules?
In this case, we have to have larger pores and there is a very simple general rule.
The pore size must be about 10 times bigger than the Stokes radius of
your molecule in order for the big molecule not to feel the size exclusion effect.